| 1 |
34791836 | Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. | 2022 Jan |
1 |
| 2 |
34865212 | Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. | 2022 Feb |
2 |
| 3 |
33735664 | Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. | 2021 Apr |
1 |
| 4 |
33963002 | Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib. | 2021 Aug 15 |
2 |
| 5 |
34127506 | TP53 Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse? | 2021 Aug 15 |
3 |
| 6 |
34521099 | Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations. | 2021 Dec 16 |
3 |
| 7 |
31180577 | Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. | 2020 Jan 1 |
1 |
| 8 |
31628428 | Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. | 2020 Mar |
1 |
| 9 |
31732977 | Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on. | 2020 Apr |
2 |
| 10 |
31924585 | PRIMA-1MET cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells. | 2020 Feb |
1 |
| 11 |
31965420 | Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia. | 2020 Oct |
2 |
| 12 |
32172299 | Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived. | 2020 Mar 14 |
1 |
| 13 |
32187452 | The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. | 2020 May |
1 |
| 14 |
32726539 | Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations. | 2020 Jul 30 |
1 |
| 15 |
32791549 | [Current diagnosis and treatment of chronic lymphocytic leukaemia]. | 2020 Aug |
2 |
| 16 |
32833105 | LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. | 2020 Oct |
2 |
| 17 |
32994268 | Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment. | 2020 Sep 29 |
1 |
| 18 |
30183082 | TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia. | 2019 Jan |
1 |
| 19 |
30338509 | Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib. | 2019 Feb |
5 |
| 20 |
30559058 | Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy. | 2019 Feb |
1 |
| 21 |
30842083 | Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. | 2019 May 9 |
1 |
| 22 |
30988561 | Reduced Dose Ibrutinib Due to Financial Toxicity in CLL. | 2019 Apr |
1 |
| 23 |
31363127 | Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes. | 2019 Jul 30 |
1 |
| 24 |
31555576 | Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal? | 2019 |
1 |
| 25 |
31648477 | [Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review]. | 2019 Sep 14 |
1 |
| 26 |
28549767 | Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies. | 2018 Mar |
1 |
| 27 |
29480432 | Frontline Therapy of CLL: Evolving Treatment Paradigm. | 2018 Apr |
1 |
| 28 |
29484684 | Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia. | 2018 Feb 27 |
1 |
| 29 |
30175400 | Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. | 2018 Nov |
2 |
| 30 |
27535981 | Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia. | 2017 Feb 15 |
4 |
| 31 |
27797975 | Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. | 2017 May 1 |
1 |
| 32 |
28130034 | NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation. | 2017 Mar |
1 |
| 33 |
28185174 | Current Treatment of Chronic Lymphocytic Leukemia. | 2017 Jan |
1 |
| 34 |
28782884 | Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. | 2017 Sep |
1 |
| 35 |
29082795 | Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia. | 2017 Dec |
1 |
| 36 |
29222275 | The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. | 2017 Dec 8 |
1 |
| 37 |
29234595 | Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature. | 2017 |
1 |
| 38 |
29250930 | Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia. | 2017 Dec |
1 |
| 39 |
27040702 | Initial therapy of chronic lymphocytic leukemia. | 2016 Apr |
1 |
| 40 |
27198718 | Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. | 2016 Dec |
1 |
| 41 |
27284738 | p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL. | 2016 Jun 10 |
2 |
| 42 |
27913471 | Sequencing of chronic lymphocytic leukemia therapies. | 2016 Dec 2 |
1 |
| 43 |
25555420 | Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. | 2015 Feb |
3 |
| 44 |
25802231 | Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia. | 2015 May |
2 |
| 45 |
25908509 | Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. | 2015 May |
1 |
| 46 |
26062943 | Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target. | 2015 |
1 |
| 47 |
26118882 | [Ibrutinib: A new drug of B-cell malignancies]. | 2015 Jun |
1 |
| 48 |
26628631 | The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. | 2015 Dec |
1 |
| 49 |
26637744 | Management of prolymphocytic leukemia. | 2015 |
1 |
| 50 |
26637745 | Prognostic markers and standard management of chronic lymphocytic leukemia. | 2015 |
1 |